Shandong Lukang Pharmaceutical Co., Ltd.SSE: 600789

Report for Q3 2025

Oct 31, 2025 · Issued by Shandong Lukang Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 31, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-312

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Shandong Lukang Pharmaceutical Co., Ltd. on 6ix

Earlier from Shandong Lukang Pharmaceutical

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025Oct 11, 2025
Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory CommissionSep 30, 2025
Announcement on Resolutions of the 9th (Extraordinary) Meeting of the 11th Board of SupervisorsSep 20, 2025
Announcement on Convening the 2025 Semi-annual Performance BriefingSep 13, 2025
Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Methocarbamol Injection and Becoming the Marketing Authorization Holder of the DrugAug 30, 2025

Later from Shandong Lukang Pharmaceutical

Announcement on the Company and Its Holding Subsidiaries Being Selected as Successful Bidders in the 11th Round of National Centralized Drug ProcurementNov 8, 2025
Prospectus for Issuance of A-shares to Specific Objects in 2024 (Registration Draft)Dec 3, 2025
Announcement on Obtaining Government SubsidiesDec 9, 2025
Announcement on Signing Trademark License Agreement with Related Parties and Related Party TransactionsDec 12, 2025
Indicative Announcement on the Issuance of A-shares to Specific Objects in 2024Dec 23, 2025

All Shandong Lukang Pharmaceutical news releases

Follow Shandong Lukang Pharmaceutical into a list and get an email when it puts out news.

Follow Shandong Lukang Pharmaceutical